Optimal treatments in cost-effectiveness analysis in the presence of covariates: improving patient subgroup definition
DOI10.1016/J.EJOR.2012.11.003zbMATH Open1292.62144OpenAlexW2022625167MaRDI QIDQ2253554FDOQ2253554
Authors: Yanyan Li 
Publication date: 27 July 2014
Published in: European Journal of Operational Research (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.ejor.2012.11.003
Recommendations
- Optimal healthcare decisions: the importance of the covariates in cost-effectiveness analysis
- Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective
- Subgroup identification and variable selection for treatment decision making
- Covariate-adjusted cost-effectiveness ratios
- A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects
- Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment
- Incorporating patients' characteristics in cost-effectiveness studies with clinical trial data: a flexible Bayesian approach
- Optimal Allocation to Treatment Groups under Variance Heterogeneity
- A general statistical framework for subgroup identification and comparative treatment scoring
- Augmenting Markov Cohort Analysis to Compute (Co)Variances: Implications for Strength of Cost-Effectiveness
subgroup analysisintrinsic priorsBayesian variable selectionutility functioncost-effectiveness analysisbivariate regression model
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10)
Cited In (8)
- Optimal healthcare decisions: comparing medical treatments on a cost-effectiveness basis
- Covariate-adjusted cost-effectiveness ratios
- Cost-effectiveness analysis for heterogeneous samples
- Optimal healthcare decisions: the importance of the covariates in cost-effectiveness analysis
- Case-Only Analysis of Treatment-Covariate Interactions in Clinical Trials
- Fuzzy approach to decision analysis with multiple criteria and uncertainty in health technology assessment
- Dynamic cost-benefit analysis of drug substitution programs
- Incorporating patients' characteristics in cost-effectiveness studies with clinical trial data: a flexible Bayesian approach
This page was built for publication: Optimal treatments in cost-effectiveness analysis in the presence of covariates: improving patient subgroup definition
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2253554)
